Risultati per: Uso dei test del DNA tumorale circolante per i pazienti con cancro

A Siena. Oggi interventi anche in anestesia locale

Le donne possono partecipare inviando un campione biologico

Fondi raccolti da 83 sezioni dell’associazione contro leucemie

Schillaci: La resistenza è un’emergenza globale. No al fai da te’

In Reply Our study adjusted the FIT cutoff to yield the same overall positivity rate as reported for the mt-sRNA test (17%) to enhance comparability of diagnostic performance of both tests. Below we address each of the 3 points made by Drs Yang and Ma.

Gastric cancer is a leading cause of cancer death globally. Although endoscopy-based screening has led to a decrease in gastric cancer mortality in Eastern Asian countries with populations at high risk, lack of risk stratification and the cost of health care infrastructure and trained personnel limit its use in most of the world. Availability of noninvasive biomarkers for the identification of high-risk individuals could optimize endoscopy-based screening programs for a more general application, including in regions where gastric cancer rates in the general population are low.

To the Editor We read with interest the recent study that compared the fecal immunochemical test (FIT) positivity threshold vs multitarget stool RNA (mt-sRNA) testing for colorectal cancer screening. However, we have concerns regarding the study methodology and the capability of FIT to fully replace the mt-sRNA panel.

Arrivano a 641 i i centri diagnostico-clinici

UniCamillus, oggi 99,6% dei piccoli trattato nel modo sbagliato

La Presidenza del Consiglio aderisce a ‘Illumina novembre’